News Conference News AHA 2025 LAAO Doesn’t Match Medical Therapy for High-risk AF Patients: CLOSURE-AF Caitlin E. Cox November 09, 2025
News Conference News AHA 2024 OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain Todd Neale November 18, 2024
Presentation AHA 2024 Efficacy and safety of EdoxabaN in anticoagulant therapy after surgical Bioprosthetic vALVe replacement Presenter: Chisato Izumi November 17, 2024
News Conference News AHA 2024 ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery Yael L. Maxwell November 17, 2024
News Conference News AHA 2020 Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib Todd Neale November 14, 2020
News Conference News AHA 2019 Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR Todd Neale November 17, 2019
News Conference News AHA 2018 Complications Following TAVR Are Going Down, US Data Show Yael L. Maxwell November 20, 2018
News Conference News AHA 2017 ‘Acceptable Safety’ for LAA Closure Seen in a Real-World, All-Comers Registry Todd Neale November 22, 2017
News Conference News AHA 2016 AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR Shelley Wood November 09, 2016